2016 Global Survey on Clinical Next-Generation Sequencing

Respondents Show Vivid Interest in Developing Clinical NGS-based Tests for Infectious Disease Testing Applications

USD 4,950

* Required Fields

USD 4,950


Be the first to review this product

The primary goal of this research is to analyze the current and future adoption plans of Next-Generation Sequencing (NGS) for clinical applications. The survey seeks to collect the following key information:

•     Outsourcing needs and clinical NGS service providers
•     Current and future interest areas of clinical NGS
•     Genetic elements of interest
•     Purchase patterns for instruments and reagents
•     Predominantly used clinical methods (e.g., chip sequencing, whole exome)
•     Perspectives of NGS used as complement or replacement for current methods
•     Platforms used for NGS clinical data interpretation
•     Predominantly cited instruments for clinical use
•     Familiarity with clinical NGS service providers
•     Factors promoting adoption
•     Factors limiting adoption
•     Best practices from labs—direct quotes from lab managers

Research Methodology
Lab managers of clinical labs were invited to participate in an online survey during August–November 2016. To qualify for survey participation, respondents had to be working in a private or public laboratory, clinical research institution, reference laboratory, academic medical center facility, hospital lab, or diagnostic company that employs NGS for clinical use. Respondents had to be constant users of this technology, belong to the scientific community, and be in a position to authorize purchases. Over 184 respondents qualified for the survey including C-level officers, lab managers, directors, physicians, post docs, and principal investigators that had a direct interference with the clinical NGS community. End users were also evaluated for their ability to authorize purchases or make product recommendations. Respondents indicated a wide range of job titles, such as lab directors, scientists, lab managers, clinicians, pathologists, and lab technicians. In total, about 82% of respondents work in the United States. Nevertheless, this study is considered global because the survey was open to respondents from all countries.

Table of Contents

2016 Global Survey on Clinical Next-Generation SequencingExecutive SummaryKey FindingsResearch Background, Objectives, Methodology, and Respondent DemographicsResearch ObjectivesResearch MethodologyResearch Methodology (continued)Demographics Technology Usage and Outsourced Respondents Respondent DemographicsRespondent Demographics (continued)Brand Familiarity of Clinical NGS ProvidersBrand Perception of Top 16 ProvidersNGS Clinical ApplicationsCurrent and Future Interest Areas for Clinical NGS TestingTop 7 Preferred Vendors for NGS Clinical Sequencing ServicesAreas of Pathogen Clinical Research and Methodology UsedNGS for Infectious Disease TestingInterest in Pursuing NGS-based Infectious Disease TestingCurrent and Future Plans in Infectious Disease TestingBrand Familiarity for Infectious Disease TestingSequencing Methods Used for TestingInfectious Disease Sequencing MethodGenetic Elements of Interest for NGS Clinical WorkCorrelation of Genetic Elements and Clinical Area of InterestCorrelation of Genetic Elements and Sequencing MethodsInstrument and Reagent Purchase PatternsInstrument and Reagent Purchase PatternsInstrument and Reagent Purchase Patterns (continued)Complemented or Replaced Instruments in LabsComplementing Instruments/MethodsInstrument Usage—Current and Future Use for Clinical Applications Analysis of Instruments and Clinical ApplicationsClinical NGS Data AnalysisNGS Data AnalysisData Analysis for Specific Infectious Disease NGS ApplicationCurrent and Future Usage of NGS Informatics PlatformsFactors Promoting Adoption of Clinical NGSFactors Limiting the Adoption of Clinical NGSFactors that Helped Overcome Obstacles to Implementing NGSLegal DisclaimerAppendixAdditional Sources of InformationThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerNorth America and Europe PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy


Related Research

Release Date : 26-Sep-17

Region : North America

Release Date : 25-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.